
Biosplice Therapeutics
Founded Year
2008Stage
Series B | AliveTotal Raised
$561.5MLast Raised
$120M | 3 yrs agoAbout Biosplice Therapeutics
Biosplice Therapeutics is a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases. Its scientific platform is based on biological discoveries that govern tissue specialization and enable it to selectively eliminate harmful proteins using small molecules. It was formerly known as Wintherix & Epitherix. It was founded in 2008 and is based in San Diego, California.
Loading...
Loading...
Biosplice Therapeutics Patents
Biosplice Therapeutics has filed 131 patents.
The 3 most popular patent topics include:
- transcription factors
- g protein coupled receptors
- clusters of differentiation

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
7/26/2022 | 11/21/2023 | Benzamides, Proteinogenic amino acids, Orthorhombic minerals, Glucogenic amino acids, Iron minerals | Grant |
Application Date | 7/26/2022 |
---|---|
Grant Date | 11/21/2023 |
Title | |
Related Topics | Benzamides, Proteinogenic amino acids, Orthorhombic minerals, Glucogenic amino acids, Iron minerals |
Status | Grant |
Latest Biosplice Therapeutics News
Nov 13, 2023
San Diego, California, UNITED STATES SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, yesterday presented results from a long-term extension study, OA-07 for its knee OA drug candidate, lorecivivint. The oral presentation was delivered in San Diego, California at the 2023 American College of Rheumatology (“ACR”) annual meeting. Results from the study support the potential for multiple injections of lorecivivint to delay structural progression and provide symptomatic benefit. “We believe these unique data highlight lorecivivint’s potential to provide structural benefit and symptom relief to the millions of patients suffering from osteoarthritis,” commented Biosplice Chief Medical Officer, Yusuf Yazici, MD. “The full results from OA-07 build upon our existing evidence, suggesting that repeat injections of lorecivivint could provide patients and physicians with both structure-modifying and symptomatic benefits. We are excited to continue to investigate lorecivivint as a treatment option for knee OA.” OA-07 was a long-term extension trial, which enrolled patients who completed OA-11, a prior 12-month Phase 3 study. The primary efficacy objective of OA-07 was to measure the structure improvement potential of lorecivivint over multiple years and multiple injections. During the first year of the OA-07 study, patients and investigators remained blinded, and patients received injections of lorecivivint on an annual basis, allowing Biosplice to capture both long-term and repeat-injection data for safety and efficacy, including pain, function, and structure. In the second year of the OA-07 trial (which is the third year of the study, including the initial year from OA-11), placebo patients crossed-over to receiving lorecivivint, and all patients remained blinded as to whether they had previously received lorecivivint or placebo. Patients who received three annual injections of lorecivivint and completed the study showed an absolute decline in mJSW of 0.06 mm versus baseline over 36 months. Patients receiving placebo injections after two years saw a decline of 0.21 mm, which is similar to average annual mJSW declines of 0.1-0.2 mm seen in population-wide studies of OA (Dupuis DE et al., Osteoarthritis and Cartilage, 2003). Comparing lorecivivint patients at 36 months to the last observation of placebo patients, a significant difference of 0.15 mm is seen (P=0.045). Assuming continued placebo progression from the last measurement point prior to crossover, consistent with longitudinal cohort studies of OA, the absolute difference between the active cohort and the placebo cohort is 0.26 mm, again a clinically and statistically significant result (P=0.001). The structural benefits of lorecivivint were even more pronounced in patients with less severe disease (KL2 population), with an absolute increase in mJSW versus baseline of 0.17 mm following 36 months of treatment and statistically significant increase versus the last measurement point of placebo subjects prior to cross-over. Furthermore, among those patients who previously had received placebo, the introduction of lorecivivint at month 24 appears to have arrested their decline in mJSW at 36 months. Please see the graphic below for data amongst the population who completed the study. OA-11 and OA-07 “Completers” – Change from OA-11 Baseline in mJSW (mm) A graphic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b9f9eb8d-1a80-4d17-964a-349f3fb955d6 . In addition to the exciting results in mJSW, the lorecivivint cohort demonstrated a statistically significant improvement in pain versus the placebo cohort prior to crossover. Consistent with the clinical program to date, lorecivivint continued to appear safe and well-tolerated, with no additional safety signals with repeat injections. A copy of the presentation materials can be seen on the Publications page of the Biosplice Therapeutics website. About Biosplice Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center. Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions. Learn more at https://www.biosplice.com Corporate Contact:
Biosplice Therapeutics Frequently Asked Questions (FAQ)
When was Biosplice Therapeutics founded?
Biosplice Therapeutics was founded in 2008.
Where is Biosplice Therapeutics's headquarters?
Biosplice Therapeutics's headquarters is located at 9360 Towne Centre Drive, San Diego.
What is Biosplice Therapeutics's latest funding round?
Biosplice Therapeutics's latest funding round is Series B.
How much did Biosplice Therapeutics raise?
Biosplice Therapeutics raised a total of $561.5M.
Who are the investors of Biosplice Therapeutics?
Investors of Biosplice Therapeutics include Eventide Asset Management, aMoon Fund, SymBiosis, Verition Fund Management, Sands Capital and 7 more.
Who are Biosplice Therapeutics's competitors?
Competitors of Biosplice Therapeutics include Chordia Therapeutics and 1 more.
Loading...
Compare Biosplice Therapeutics to Competitors
Lubris BioPharma operates as a biopharmaceutical company. It develops recombinant human lubricin for the treatment of dry eye, osteoarthritis, surgical adhesions, xerostomia, and pericarditis. It was founded in 2011 and is based in Weston, Massachusetts.
Chordia Therapeutics is a bio-venture company specializing in cancer research and development. Chordia's programs include preclinical CDC-like kinase (CLK) inhibitors with applications in cancer and an adult T-cell leukemia-lymphoma drug. The company serves customers in the healthcare sector. It was founded in 2017 and is based in Fujisawa, Japan.

Oyster Point Pharma (NASDAQ: OYST) is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of therapies to treat diseases with high unmet needs. The company's initial focus is to develop therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. The company was founded in 2015 and is based in Princeton, New Jersey. In January 2023, Oyster Point Pharma was acquired by Viatris.

Aldeyra Therapeutics is a company focused on the discovery and development of innovative therapies for immune-mediated diseases in the healthcare sector. The company's main offerings include the development of medicines that modulate immunological systems to treat ocular and systemic conditions such as dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy. Aldeyra primarily serves the healthcare industry, particularly in the area of immune-mediated diseases. It is based in Lexington, Massachusetts.

Bioventus (NASDAQ: BVS) is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing.
Loading...